Taking a specific form of lycopene (lycosome-formulated) daily for 30 days is linked to a threefold decrease in antibodies against Chlamydia pneumoniae in people with coronary vascular disease. Another form of lycopene (lactolycopene) does not produce this effect.
See the scientific wording
Lycosome-formulated lycopene supplementation (7 mg daily for 30 days) is associated with a threefold reduction in Chlamydia pneumoniae IgG levels in patients with coronary vascular disease, whereas lactolycopene shows no such effect.
Very strong evidence
Randomized trialsOne moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2018
The study gave heart disease patients a special type of lycopene for a month and found that their antibodies against a certain bacteria dropped by three times, just like the claim says. Another type of lycopene didn't help, also matching the claim.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A special form of lycopene, called lycosome, helps the body absorb more lycopene into the blood. Once in the blood, lycopene acts like a sponge to soak up harmful free radicals that damage cells and cause inflammation. By removing these free radicals, lycopene lowers oxidative stress and reduces the body's inflammatory response, which is measured by a drop in antibodies against a bacteria called Chlamydia pneumoniae.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Taking a specific form of lycopene (lycosome-formulated) daily for 30 days is linked to a threefold decrease in antibodies against Chlamydia pneumoniae in people with coronary vascular disease. Another form of lycopene (lactolycopene) does not produce this effect.
Mechanism
1 studyThe special lycosome coating helps the body absorb more lycopene. Lycopene then acts as an antioxidant, cleaning up harmful molecules that cause damage and inflammation. This cleanup lowers the body's inflammatory response, including the specific antibodies linked to Chlamydia pneumoniae infection.
A special form of lycopene, called lycosome, helps the body absorb more lycopene into the blood. Once in the blood, lycopene acts like a sponge to soak up harmful free radicals that damage cells and cause inflammation. By removing these free radicals, lycopene lowers oxidative stress and reduces the body's inflammatory response, which is measured by a drop in antibodies against a bacteria called Chlamydia pneumoniae.
Lycosome formulation protects lycopene from degradation and enhances its absorption in the intestine, leading to a significant increase in lycopene levels circulating in the blood.
Increased circulating lycopene scavenges free radicals, reducing oxidative damage to lipids (measured as oxidized LDL) and other biomolecules (measured as inflammatory oxidative damage).
Reduced oxidative stress attenuates the inflammatory response, as reflected by decreased levels of Chlamydia pneumoniae IgG, a marker of chronic inflammation.
Evidence from Studies
Supporting (1)
Community contributions welcome
Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary vascular disease
The study gave heart disease patients a special type of lycopene for a month and found that their antibodies against a certain bacteria dropped by three times, just like the claim says. Another type of lycopene didn't help, also matching the claim.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of RCTs on Lycosome-Formulated Lycopene and Chlamydia pneumoniae IgG in CVD Patients
Systematic review and meta-analysis of double-blind RCTs comparing lycosome-formulated lycopene (7 mg daily for ≥30 days) vs placebo in patients with coronary vascular disease, measuring Chlamydia pneumoniae IgG levels at baseline and post-intervention.
Double-Blind RCT of Lycosome-Formulated Lycopene vs Placebo on Chlamydia pneumoniae IgG in CVD Patients
Double-blind, placebo-controlled RCT with coronary vascular disease patients (n≥100) randomized to lycosome-formulated lycopene (7 mg daily) or placebo for 30 days, measuring Chlamydia pneumoniae IgG levels at baseline, 30 days, and follow-up.
Prospective Cohort Study of Lycopene Supplementation and Chlamydia pneumoniae IgG in CVD Patients
Prospective cohort of coronary vascular disease patients (n≥500) followed for 30 days, recording lycosome-formulated lycopene supplement use and measuring Chlamydia pneumoniae IgG at enrollment and end of study, with multivariable adjustment for age, sex, comorbidities, and medications.
Case-Control Study of Lycosome-Formulated Lycopene Intake and Chlamydia pneumoniae Serology in CVD Patients
Case-control study with coronary vascular disease patients: cases with low Chlamydia pneumoniae IgG (≤ threshold) and controls with high IgG, matched for age, sex, and CVD severity; assess history of lycosome-formulated lycopene supplement use via questionnaire or records.
Cross-Sectional Study of Current Lycosome-Formulated Lycopene Use and Chlamydia pneumoniae IgG in CVD Patients
Cross-sectional survey of coronary vascular disease patients (n≥200) measuring current lycosome-formulated lycopene supplement use and Chlamydia pneumoniae IgG levels, with adjustment for confounders.